{"id":"NCT02970292","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-26","primaryCompletion":"2019-05-28","completion":"2019-06-25","firstPosted":"2016-11-22","resultsPosted":"2020-06-17","lastUpdate":"2020-06-17"},"enrollment":396,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pimavanserin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia","primaryOutcome":{"measure":"Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"From baseline to Week 6","effectByArm":[{"arm":"Pimavanserin","deltaMin":88.3,"sd":0.68},{"arm":"Placebo","deltaMin":88.1,"sd":0.61}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0940"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":105,"countries":["United States","Bulgaria","Canada","Czechia","Hungary","Lithuania","Poland","Russia","Serbia","Ukraine"]},"refs":{"pmids":["38264323"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":198},"commonTop":["Headache","Somnolence","Insomnia"]}}